Hemogenyx Pharmaceuticals (HEMO) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Jul 2025 07:00 AM
RNS
Hemogenyx Awarded Grant
30 Jun 2025 07:00 AM
RNS
Total Voting Rights
17 Jun 2025 07:00 AM
RNS
Clearance to Proceed with Pediatric Expansion
03 Jun 2025 02:02 PM
RNS
Placing to Raise £451,250 and Director’s Dealing
03 Jun 2025 07:00 AM
RNS
Second Patient Passes Initial Safety Tests
30 May 2025 03:14 PM
RNS
Total Voting Rights
29 May 2025 02:06 PM
RNS
Result of AGM
14 May 2025 07:00 AM
RNS
Pediatric Amendment to Clinical Protocol
13 May 2025 07:00 AM
RNS
AGM Correction
08 May 2025 07:00 AM
RNS
Placing to Raise £451,250 and Director’s Dealing
02 May 2025 04:24 PM
RNS
Notice of AGM
02 May 2025 07:00 AM
RNS
Second Patient Treated with HG-CT-1 CAR-T Therapy
28 Apr 2025 07:00 AM
RNS
Final Results
03 Apr 2025 07:00 AM
RNS
FDA Annual Report
31 Mar 2025 07:00 AM
RNS
Total Voting Rights
24 Mar 2025 07:00 AM
RNS
First Patient Safety
17 Mar 2025 07:00 AM
RNS
Recruitment of Second Patient for Clinical Trials
13 Mar 2025 03:10 PM
RNS
Conversion of convertible loan notes
11 Mar 2025 07:00 AM
RNS
Institutional investment
24 Feb 2025 07:00 AM
RNS
First-in-Human Treatment with HG-CT-1
19 Feb 2025 04:50 PM
RNS
Issue of convertible loan notes
31 Jan 2025 09:35 AM
RNS
Total Voting Rights
08 Jan 2025 07:00 AM
RNS
Placing to raise £340,000
02 Jan 2025 07:00 AM
RNS
Change of Company Secretary and Registered Office
31 Dec 2024 07:00 AM
RNS
Total Voting Rights
30 Dec 2024 07:00 AM
RNS
Opening of First Clinical Site
19 Dec 2024 07:00 AM
RNS
Ultrafast CAR-T Manufacturing
10 Dec 2024 04:10 PM
RNS
Admission of New Ordinary Shares and New ISIN
09 Dec 2024 01:30 PM
RNS
Result of Extraordinary General Meeting
09 Dec 2024 07:00 AM
RNS
Site Initiation Visit Completed
06 Dec 2024 07:00 AM
RNS
CBR Macrophage Delivery Update
29 Nov 2024 07:00 AM
RNS
Total Voting Rights
22 Nov 2024 12:49 PM
RNS
Notice of Extraordinary General Meeting
22 Nov 2024 07:00 AM
RNS
IRB Approval for Phase I Clinical Trial
11 Nov 2024 07:00 AM
RNS
Institutional Investment
30 Oct 2024 07:00 AM
RNS
Schedule for Phase I Clinical Trial Opening
02 Oct 2024 11:19 AM
RNS
Strategic Investment from Prevail Partners, LLC
27 Sep 2024 07:00 AM
RNS
Half-year Report
09 Sep 2024 07:00 AM
RNS
FLT3 Assay Ready for Phase I Trials at MD Anderson
02 Sep 2024 07:00 AM
RNS
CDX Development Update
28 Aug 2024 07:00 AM
RNS
Presentation at CBD S&T Conference
29 Jul 2024 07:00 AM
RNS
Macrophage-Directed Therapies Summit Presentation
27 Jun 2024 04:39 PM
RNS
Result of Annual General Meeting
17 Jun 2024 07:00 AM
RNS
Operations Update
03 Jun 2024 07:00 AM
RNS
Posting of Annual Report & Notice of AGM
25 Apr 2024 07:00 AM
RNS
Final Results
28 Mar 2024 07:00 AM
RNS
Total Voting Rights
29 Feb 2024 07:00 AM
RNS
Placing to Raise US$4.2 million
16 Feb 2024 07:00 AM
RNS
CBR Brain Delivery
14 Feb 2024 07:00 AM
RNS
CBR Intranasal Delivery

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

Hemo share price launched on LSE at 3p in 2017.

UK 100

Latest directors dealings